$144.53
20.64%
Nasdaq, Nov 19, 03:59 pm EST. Closed.
ISIN
US4576693075
Symbol
INSM

Insmed Incorporated Stock News

Positive
●
Proactive Investors
●
about 3 hours ago
Insmed Incorporated (NASDAQ:INSM) shares surged on Thursday after reports that French pharmaceutical group Sanofi is considering an acquisition of the US biotechnology company, which has a market value of about $26.28 billion. On Thursday afternoon, Insmed was trading at $141.84, up $22.04, or 18.4%.
Positive
●
Barrons
●
about 11 hours ago
Insmed stock jumps following a report saying Sanofi is eyeing a takeover of the biopharma company.
Neutral
●
PRNewsWire
●
22 days ago
—Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ®  (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Quarter of 2026— —ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $124.4 Million for the Third Quarter of 2026, Reflecting 9% Growth Over the Third Quarter of 2025— —Company Raises 20...
Neutral
●
PRNewsWire
●
about one month ago
—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J., Oct. 20, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of pati...
Neutral
●
PRNewsWire
●
about one month ago
—BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan— BRIDGEWATER, N.J., Oct. 19, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing ser...
Neutral
●
PRNewsWire
●
about one month ago
—Insmed's Largest Parallel-Running Clinical Effort to Date With Four Pivotal Phase 3 Studies Advancing Across Four Progressive Pulmonary Diseases: PALM-PAH, PALM-ILD, PALM-PPF, and PALM-IPF— —One of the Broadest Active Global Clinical Programs in the Pulmonary Space, With the Potential to Redefine Prostanoid Therapy for These Patient Populations— BRIDGEWATER, N.J., Oct. 15, 2026 /PRNewswire/ --...
Neutral
●
PRNewsWire
●
about 2 months ago
— Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership — — Company Reaffirms Full-Year 2026 Financial Guidance — — Company Announces Third-Quarter 2026 Financial Results Conference Call to Be Held on Thursday, October 29, 2026 — BRIDGEWATER, N.J., Oct. 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutica...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today